Vaccine by Raczniak, Gregory A. et al.
Duration of protection against hepatitis A for the current two-
dose vaccine compared to a three-dose vaccine schedule in 
children
Gregory A. Raczniaka,b,*, Timothy K. Thomasc, Lisa R. Bulkowa, Susan E. Negusd, Carolyn 
L. Zanisa, Michael G. Brucea, Philip R. Spradlinge, Eyasu H. Teshalee, and Brian J. 
McMahona,d
aArctic Investigations Program, Division of Preparedness and Emerging Infections, National 
Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and 
Prevention, 4055 Tudor Centre Drive, Anchorage, AK 99508, USA
bEpidemic Intelligence Service, Division of Applied Sciences, Scientific Education and 
Professional Development Program Office, Centers for Disease Control and Prevention, 1600 
Clifton Road NE, Atlanta, GA 30333, USA
cDivision of Community Health Services, Alaska Native Tribal Health Consortium, 4000 
Ambassador Drive, Inuit 127, Anchorage, AK 99508, USA
dLiver Disease and Hepatitis Program, Division of Community Health Services, Alaska Native 
Tribal Health Consortium, 4315 Diplomacy Drive, Anchorage, AK 99508, USA
eEpidemiology and Surveillance Branch, Division of Viral Hepatitis, National Center for HIV/AIDS, 
Viral Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
Abstract
Background—Hepatitis A is mostly a self-limiting disease but causes substantial economic 
burden. Consequently, United States Advisory Committee for Immunization Practices 
recommends inactivated hepatitis A vaccination for all children beginning at age 1 year and for 
high risk adults. The hepatitis A vaccine is highly effective but the duration of protection is 
unknown.
Methods—We examined the proportion of children with protective hepatitis A antibody levels 
(anti-HAV ≥20 mIU/mL) as well as the geometric mean concentration (GMC) of anti-HAV in a 
cross sectional convenience sample of individuals aged 12–24 years, who had been vaccinated 
with a two-dose schedule in childhood, with the initial dose at least 5 years ago. We compared a 
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subset of data from persons vaccinated with two-doses (720 EL.U.) at age 3–6 years with a 
demographically similar prospective cohort that received a three-dose (360 EL.U.) schedule and 
have been followed for 17 years.
Results—No significant differences were observed when comparing GMC between the two 
cohorts at 10 (P = 0.467), 12 (P = 0.496), and 14 (P = 0.175) years post-immunization. For the 
three-dose cohort, protective antibody levels remain for 17 years and have leveled-off over the 
past 7 years.
Conclusion—The two- and three-dose schedules provide similar protection >14 years after 
vaccination, indicating a booster dose is not needed at this time. Plateauing anti-HAV GMC levels 
suggest protective antibody levels may persist long-term.
Keywords
Hepatitis A virus; Inactivated hepatitis A vaccine; RNA viruses; Enterovirus infections
1. Introduction
In the early 1990s, Alaska Native (AN) persons had an annual incidence of hepatitis A virus 
(HAV) infection that was approximately 40 times higher than that of non-Native Alaska 
residents, with outbreaks occurring among AN persons approximately every 7–10 years 
[1,2]. A pre-licensure clinical trial of hepatitis A vaccine was conducted at the time in 
children 3–6 years of age. This cohort has been followed regularly since then to determine 
long-term protection. This study used a three-dose regimen consisting of half the antigen 
(360 EL.U.) in each dose of the current licensed two-dose regimen (720 EL.U.) otherwise 
the vaccines were similar hepatitis A viral protein adsorbed on similar adjuvant [3]. We 
reported results from this study showing excellent interim protective levels of antibody to 
hepatitis A antigen (anti-HAV) at 10, 15 and 17 years [4–6].
To determine if the currently licensed two-dose regimen provides long-term protection 
comparable to the three-dose regimen, we recruited AN children who participated in a 
hepatitis B booster dose study and received two doses of hepatitis A vaccine after 1 year of 
age [7]. Others have reported the long term clinical results of the two-dose vaccination 
schedule in other geographical areas [8–10], herein we compare two-dose vaccination to the 
three-dose vaccination which is the longest followed cohort for HAV immunization.
2. Subjects and methods
2.1. Subjects
This study was approved by the Institutional Review Boards of the Alaska Area Native 
Health Service, Indian Health Service, and Centers for Disease Control and Prevention, as 
well as by two Alaska Native health organizations, the Southcentral Foundation and the 
Alaska Native Tribal Health Consortium. Consent to participate was received from one 
parent or guardian at the start of the study. At the time of recruitment, no participants 
reported any illness that included jaundice or icterus and none had been diagnosed with 
acute hepatitis. Medical records on each participant were reviewed and none revealed illness 
consistent with acute hepatitis A.
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2.2.1. Two-dose cohort—A cohort of Alaska Native individuals participated in a long-
term hepatitis B vaccine protection study. They had received a hepatitis B vaccine series 
(Recombivax®) starting at birth. From this group, we selected a convenience sample of 
children who had received hepatitis A vaccine after 1 year of age during a “catch-up” 
hepatitis A vaccination campaign offered to all children in Alaska. We attempted to obtain 
100 participants who met our criteria for timely vaccination, a second dose within 6–12 
months of the first dose, and recruit an equal number of children who received their first 
dose between 1–4, 5–9 and above 10 years of age. All participants were consented at the 
time of blood draw. Participants had received two doses of hepatitis A vaccine either 
HAVRIX™ (GlaxoSmithKline Biologicals, Rixenart, Belgium) or VAQTA ® (Merck, New 
Jersey, USA). Both vaccine doses contained 720 ELISA units [EL.U.] of hepatitis A viral 
protein adsorbed on aluminum hydroxide adjuvant, volunteers were vaccinated with the 
second dose between 6 and 12 months after the initial dose. The majority received the first 
dose of hepatitis A vaccine between 1–4 years (50.5%) of age followed by ages 5–9 (31.7%) 
and over 10 years of age (17.8%). We used the mean value of years since last vaccination to 
categorize the follow-up groups: specifically, the group evaluated 7.5 to <9 (mean: 8.2) 
years after second vaccination is designated the 8-year follow-up, the group evaluated 9 to 
<11 (mean: 10.2) years after second vaccination is designated the 10-year follow-up, the 
group evaluated 11 to <13 (mean: 12.4) years after second vaccination is designated the 12-
year follow-up, and the group evaluated 13 to <15 (mean: 14.2) years after second 
vaccination is designated the 14-year follow-up.
2.2.2. Three-dose cohort—The original prospective three-dose cohort was comprised of 
144 Alaska Native children (age 3–6 years) recruited for long-term follow-up and invited to 
be tested yearly for the first 5 years then approximately every 2 years thereafter. These 
volunteers were randomized to receive the inactivated hepatitis A vaccine, HAVRIX™ (360 
EL.U. of hepatitis A viral protein adsorbed on aluminum hydroxide adjuvant with 0.5% w/v 
2-phenoxyethanol as preservative, GlaxoSmithKline Biologicals, Rixenart, Belgium) on one 
of three schedules: “A” (0, 1, 2 months, n = 51), “B” (0, 1, 6 months, n = 46), or “C” (0, 1, 
12 months, n = 47). For this analysis, we combined the three-dose cohorts (A, B, and C) into 
a single data set because at 10, 12, or 14 year follow-up periods after second vaccine dose 
these groups did not have statistically different anti-HAV GMC [4–6]. In addition, we 
recruited as many participants as possible for each time point. Not all volunteers could be 
reached or could participate at each time point; however, only those volunteers that received 
additional doses of HAV (more than three) were excluded from participating in future time 
points.
2.3. Laboratory methods
Sera were tested for anti-HAV using a modified ELISA (DiaSorin) assay. The results are 
quantitatively expressed in milli-international units (mIU) per milliliter (mL) with anti-HAV 
concentrations ≥20 mIU/mL, the lower limit of detection of the assay, were considered 
protective and this limit has been used in previous publications as the standard for protective 
anti-HAV. The methodology for this assay was the same as used in the long-term three-dose 
study [4–6].
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All anti-HAV levels were log-transformed and analyzed using simple (two-dose schedule, 
cross-sectional convenience cohort) and repeated measures (three-dose schedule, 
prospective longitudinal cohort) analysis of variance (ANOVA). Data are reported as 
geometric mean concentrations (GMC) by vaccination schedule. Participants were stratified 
by age when the first vaccination dose was administered and time of follow-up since 
completing the last dose for the two-dose schedule. We compare anti-HAV GMC of 
demographically similar cohorts (age, ethnicity, gender) who received the two-dose to those 
who received the earlier three-dose vaccine; both of these cohorts represent volunteers that 
received their first dose of vaccine at 3–6 years of age.
3. Results
3.1. Effect of primary vaccination with a two dose schedule
The participants in this study (n = 101) had an average age of 17.6 years (min: 12.7 years, 
max: 23.4 years) and the time elapsed since the second dose of vaccine was an average of 
11.1 years (range: 3.5–15.1 years; Table 1). When comparing groups who received the first 
vaccination at different ages (1–2, 3–6, and ≥7 years), the anti-HAV GMC levels were not 
statistically different (P > 0.05) at the 8, 10, 12, or 14 year follow-up after second vaccine 
dose (Table 2), although those vaccinated at 1–2 years consistently had the lowest average 
GMC levels at each time point. Five (5%) of the 101 participants, all ≥11 years after the 
second dose, had anti-HAV GMC < 20 mIU/ml, below the seroprotective level.
3.2. Comparison of primary vaccination with a two dose schedule versus a three dose 
schedule
We compare children in the two-dose cohort with those in the three-dose cohort who 
received the first vaccination dose between 3 to 6 years of age (Table 1). For any given 
follow-up time period, GMC levels were not statistically different (P > 0.05) comparing the 
three-dose to the two-dose vaccine schedule (Table 3). Additionally, comparing the anti-
HAV GMCs at the 10, 12, 14, and ≥15 year follow up periods within the two-dose (GMC: 
160, 298, 80, 43 mIU/mL) or within the three-dose vaccine schedule (GMC: 232, 201, 183, 
210 mIU/mL), there were no statistically significant differences in GMCs over the 5 year 
time span (P = 0.836 and P = 0.300, respectively). Nearly every person immunized between 
3–6 years of age on the two-dose or three-dose schedules demonstrated anti-HAV 
seroprotective levels (Table 4).
4. Discussion
Prior to 1996, Alaska Native people had the highest incidence of acute hepatitis A in the 
United States. A pre-licensure clinical trial of inactivated hepatitis A vaccine using a three-
dose schedule was conducted in Alaska Native children ages 3–6 that found that the vaccine 
was 100% immunogenic and safe [4,5]. Initially the three-dose schedule was licensed and 
later the dosing regimen was modified to a two-dose that was found to be equally protective. 
Alaska became the first US state to institute universal hepatitis A vaccination for all children 
in 1996 and is required for school entry. Compliance is excellent with 93% of Alaska 
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adolescents having a complete hepatitis A vaccination schedule [11]. As a result, within a 
very short time span after universal vaccination was begun, the annual incidence of hepatitis 
A is now <1/100,000; the lowest in the world [12]. Thus, we believe there is no reservoir of 
HAV present to result in natural boosting in this population. Albeit, Alaska has isolated rural 
communities including some without a consistent source of treated water or sewer service 
and conditions exist that favor the return of hepatitis A outbreaks. Thus, it is crucial to keep 
vaccination a priority and demonstrate the long-term immunogenicity for both the two- and 
three-dose regimens to determine if booster doses are needed for protection.
The data presented in this report demonstrate that the currently licensed two-dose regimen of 
hepatitis A vaccine given in childhood is able to provide serologic levels of protection for at 
least 14 years in a geographically distinct cohort. Our data are unique in that we can 
compare them to a demographically similar cohort that has been followed for a longer 
period of time. Data from our study demonstrate that GMC values of the three-dose 
immunization cohort and the 14 year two-dose immunization cohort are not statistically 
different. Regardless of vaccine manufacturer (Merck or GlaxoSmithKline) that was used, 
the long-term immunogenicity is excellent. Thus, we predict the two-dose schedule will 
follow the same trend as the three-dose study and immunogenicity will persist at similar 
levels until at least 17 years. Two previous studies on the long-term immunogenicity of 
hepatitis A vaccine using the 2 dose schedule in children and adolescence have shown 
excellent long-term immunogenicity at 10 years [8,10]. Another study compared a two- and 
three-dose schedule using a combination hepatitis A and B vaccine with the same amount of 
antigen as in our study and demonstrated good immunogenicity at 10 years and the 
vaccination schedules elicit immune responses that are not statistically different [9].
Our comparative study has limitations. The numbers of participants in the cohorts are 
relatively small and data obtained on the two-dose cohort is cross-sectional whereas the 
three-dose study is a longitudinal follow-up of the same individuals tested over time.
Our group and others have used repeated measures log-linear mathematical models in the 
past to predict how long protective anti-HAV GMCs should remain above the minimum 
seroprotective level of 20 mIU/mL. These models predicted rates of decline for anti-HAV 
GMCs to persist above seroprotective levels for 15–32 years [4,5,13–16]. However, we 
observed no statistically significant difference between anti-HAV GMCs recorded between 
10 and 14 years in this two-dose vaccine regimen and we have reported that they are also not 
different between 10 and 17 years for the three-dose immunization schedule [6]. Therefore 
the previously predicted rates of decline for anti-HAV GMC may significantly 
underestimate the longevity of seroprotective levels.
In order to show long-term protection beyond 14 or 17 years, continued observation of these 
cohorts and testing is required to determine whether booster doses are indicated. Now that 
we have shown no difference in the long-term immunogenicity between these cohorts, we 
plan to continue to follow only the three-dose cohort since we feel that the longitudinal data 
obtained will be the most valuable in determining how long protection will last and if 
booster doses are needed in this population. Our data support the conclusion that protective 
levels of anti-HAV persist and that observed levels of anti-HAV are not artificially elevated 
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by natural boosting (i.e. participants being exposed to infected persons) due to the high 
vaccination rates in children and fall in acute HAV incidence [12,17,18]. We speculate that 
in areas of high or intermediate endemicity, the GMC years after primary vaccination could 
be higher due to “natural boosting.” In these areas it is possible that just one dose of 
hepatitis A may be sufficient to provide prolonged protection. We have found in previous 
studies this population that almost 100% achieve protective levels of anti-HAV after just one 
dose of vaccine [19] and that even when the second dose of vaccine was delayed up to 30 
months, all persons had a booster response to the second dose. [20]
Acknowledgments
We thank the Alaskan study volunteers and their parents for continued support and participation. Without 
contributions from the entire staff at the Alaska Native Tribal Health Consortium, Liver Disease and Hepatitis 
Program as well as the Centers for Disease Control and Prevention, Arctic Investigations Program, this work would 
not be possible.
Financial support: This work was supported by Centers for Disease Control and Prevention through a Cooperative 
Agreement Grant to the Alaska Native Tribal Health Consortium [U50/CCU022279 and U01PS001097].
Abbreviations
GMC geometric mean concentration
anti-HAV hepatitis A antibody
AN Alaska Native persons
HAV hepatitis A virus
References
1. Bulkow LR, Wainwright RB, McMahon BJ, Middaugh JP, Jenkerson SA, Margolis HS. Secular 
trends in hepatitis A virus infection among Alaska Natives. J Infect Dis. 1993; 168:1017–20. 
[PubMed: 8376812] 
2. Peach D, McMahon BJ, Bulkow L, Funk E, Harpaz R, Margolis HS. Impact of recurrent epidemics 
of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska. J Infect Dis. 2002; 
186:1081–5. [PubMed: 12355357] 
3. McMahon BJ, Williams J, Bulkow L, Snowball M, Wainwright R, Kennedy M, et al. 
Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and 
non-Native adults. J Infect Dis. 1995; 171:676–9. [PubMed: 7876615] 
4. Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, et al. Persistence of 
antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. 
2008; 198:1776–82. [PubMed: 18976095] 
5. Byrd KK, Bruden DL, Bruce MG, Bulkow LR, Zanis CL, Snowball MM, et al. Long-term 
immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years. Journal of Pediatric 
Infectious Diseases. 2010; 5:321–7.
6. Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, et al. Long-term 
immunogenicity of hepatitis a virus vaccine in alaska 17 years after initial childhood series. J Infect 
Dis. 2013; 207:493–6. [PubMed: 23204169] 
7. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, et al. Differences in 
response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated 
during infancy. Pediatrics. 2007; 120:e373–81. [PubMed: 17636112] 
Raczniak et al. Page 6













8. Bian GL, Ma R, Dong HJ, Ni HX, Hu FJ, Chen YR, et al. Long-term clinical observation of the 
immunogenicity of inactivated hepatitis A vaccine in children. Vaccine. 2010; 28:4798–801. 
[PubMed: 20471440] 
9. Beran J, Kervyn D, Wertzova V, Hobzova L, Tichy P, Kuriyakose S, et al. Comparison of long-term 
(10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B 
vaccine in adolescents. Vaccine. 2010; 28:5993–7. [PubMed: 20637766] 
10. van Damme P, Kafeja F, Van Der Wielen M, Leyssen M, Jacquet JM. Long-term immunogenicity 
and immune memory after two doses of the adult formulation of a combined hepatitis A and B 
vaccine in children 1 to 11 years of age. Pediatr Infect Dis J. 2011; 30:703–5. [PubMed: 
21346683] 
11. Dorell CG, Yankey D, Byrd KK, Murphy TV. Hepatitis A vaccination coverage among 
adolescents in the United States. Pediatrics. 2012; 129:213–21. [PubMed: 22271690] 
12. Singleton RJ, Hess S, Bulkow LR, Castrodale L, Provo G, McMahon BJ. Impact of a statewide 
childhood vaccine program in controlling hepatitis A virus infections in Alaska. Vaccine. 2010; 
28:6298–304. [PubMed: 20637769] 
13. Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, Briantais P, et al. 
Mathematical models for assessment of long-term persistence of antibodies after vaccination with 
two inactivated hepatitis A vaccines. J Med Virol. 2000; 60:1–7. [PubMed: 10568755] 
14. Chan CY, Lee SD, Yu MI, Wang YJ, Chang FY, Lo KJ. Long-term follow-up of hepatitis A 
vaccination in children. Vaccine. 1999; 17:369–72. [PubMed: 9987176] 
15. Fan PC, Chang MH, Lee PI, Safary A, Lee CY. Follow-up immunogenicity of an inactivated 
hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine. 1998; 16:232–5. 
[PubMed: 9607035] 
16. Maiwald H, Jilg W, Bock HL, Loscher T, Sonnenburg F. Long-term persistence of anti-HAV 
antibodies following active immunization with hepatitis A vaccine. Vaccine. 1997; 15:346–8. 
[PubMed: 9141202] 
17. Byrd KK, Redd JT, Holman RC, Haberling DL, Cheek JE. Changing trends in viral hepatitis-
associated hospitalizations in the American Indian/Alaska Native population, 1995–2007. Public 
Health Rep. 2011; 126:816–25. [PubMed: 22043097] 
18. McLaughlin, J.; Castordale, L. Alaska Epidemiology Bulletin. 2010 Annual (January–December) 
Infectious Disease Report. 2011. http://www.epi.alaska.gov/bulletins/docs/b2011_07.pdf
19. Williams J, Fox-Leyva L, Christensen C, Fisher D, Schlicting E, Snowball M, et al. Hepatitis A 
vaccine administration: comparison between jet-injector and needle injection. Vaccine. 2000; 
18:1939–43. [PubMed: 10699344] 
20. Williams JL, Bruden DA, Cagle HH, McMahon BJ, Negus SE, Christensen CJ, et al. Hepatitis A 
vaccine: immunogenicity following administration of a delayed immunization schedule in infants, 
children and adults. Vaccine. 2003; 21:3208–11. [PubMed: 12804849] 
Raczniak et al. Page 7

























Raczniak et al. Page 8
Table 1
Demographic characteristics of participants.
Schedule Characteristics, all participants
Total (n) Age at first dose, mean (range), years Female sex, n (%) Alaska Native/American Indian, n (%)
Two-dose 101 5.4 (1.0–16.7) 54 (53%) 101 (100%)
Three-dose 81 4.5 (3.1–6.1) 45 (56%) 81 (100%)
Characteristics, children immunized with first dose between ages 3–6 years
Two-dose 24 5.1 (3.1–6.9) 13 (54%) 24 (100%)
Three-dose 81 4.5 (3.1–6.1) 45 (56%) 81 (100%)
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Table 2
Geometric mean concentrations (GMC) and 95% Confidence Intervals (CI) of antibody to hepatitis A virus 
(Anti-HAV) by follow up period after completing primary vaccination schedule and by age at first dose 
among a cohort of Alaska Native children who received two doses of vaccine.
Follow-up since second dose 
of HAV (years)









< 7.5 none none 148 (n = 1) (N/A) N/A
≥ 7.5 to < 9 48 (n = 1) (N/A) 115 (n = 3) (12, 1114) 125 (n = 3) (11, 1358) 0.688
≥ 9 to < 11 144 (n = 10) (78, 263) 160 (n = 7) (94, 271) 201 (n = 17) (117, 343) 0.634
≥ 11 to < 13 98 (n = 26) (66, 147) 298 (n = 8) (51, 1749) 211 (n = 11) (112, 397) 0.054
≥ 13 to < 15 21 (n = 5) (6, 77) 80 (n = 5) (40, 159) 81 (n = 1) (N/A) 0.081
≥ 15 none 43 (n = 1) (N/A) none N/A
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Table 3
Geometric mean concentrations (GMC) and 95% Confidence Intervals (CI) of hepatitis A virus (Anti-HAV) 
antibody by follow up time period after completing primary vaccination schedule and vaccination schedule 
used in Alaska Native children initially immunized between 3–6 years.
Follow-up since second dose of 
HAV (years)
Vaccination Schedule P value comparing 3 and 2 dose 
schedules
3 Dose 2 Dose
Anti-HAV GMC (mIU/mL) 
(95% CI)
Anti-HAV GMC (mIU/mL) 
(95% CI)
10 232 (n = 62) (165, 327) 160 (n = 7) (94, 271) 0.467
12 201 (n = 49) (135, 300) 298 (n = 8) (51, 1749) 0.496
14 183 (n = 56) (128, 261) 80 (n = 5) (40, 159) 0.175
≥ 15 210 (n = 58) (136, 325) 43 (n = 1) (N/A) N/A
P value comparing each follow-up 
interval
0.300 0.836
At each follow up period, we recruited all available participants that had not received additional booster doses of inactivated hepatitis A vaccine. 
The P values listed below the table compare the anti-HAV GMC observed at the listed follow-up interval by the type of vaccination schedule.
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Table 4
Proportion with seroprotective antibody levels to hepatitis A virus (≥20 mIU/mL) by follow up time period 
and vaccination schedule among Alaska Native children initially immunized between 3–6 years of age.
Vaccination Schedule Follow-up since second dose of HAV (years)
10 12 14 ≥ 15
two-dose 7 (100%) of 7 8 (100%) of 8 5 (100%) of 5 1 (100%) of 1
three-dose 62 (100%) of 62 46 (94%) of 49 53 (95%) of 56 54 (93%) of 58
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